LLY Stock Analysis — Eli Lilly and Company
Sector: Healthcare
AI Verdict
LLY trades at 27.3x next year's earnings while analysts expect +45.4% EPS growth—this is cheap for the growth on offer if their obesity and diabetes drug moat holds up.
Competitive Moat
Eli Lilly holds a defensible position in obesity and diabetes treatment with proprietary drugs like Mounjaro and Zepbound, which have shown superior efficacy and are protected by patents. Their deep clinical pipeline and regulatory expertise create high barriers for competitors aiming to replicate their success in these high-growth therapeutic areas.
Summary
LLY's blockbuster obesity and diabetes drugs are driving both explosive earnings growth and investor attention.
Where It Stands
LLY is up 62.01% over the past year, with an RSI of 50.6 signaling neutral momentum, and trades at 27.3x next year's earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 50.6 — Neutral
- Trailing P/E: 39.7x
- Forward P/E: 27.3x
- PEG Ratio: 0.91
- Earnings Growth: +0.5%
- Market Cap: $1.12T
- 1-Year Return: 62.01%
Analyst Consensus
30 Buy · 7 Hold · 1 Sell (38 analysts)
Bull Case
With forward EPS growth expected at 45.4% and a forward P/E of 27.3x, you're paying a modest premium for unusually rapid earnings expansion in pharma.
Bear Case
If the forward P/E compresses to the sector median of 22x, the stock would need to drop about 19%, erasing much of the recent outperformance.
Catalyst to Watch
Upcoming clinical trial results or regulatory approvals for new obesity or diabetes drugs could either reinforce or challenge the current growth expectations.